• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Evidence mounts linking aspirin to lower risk of ovarian cancer

Bioengineer by Bioengineer
October 4, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

TAMPA, Fla. — Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported taking a low-dose aspirin every day had a 23 percent lower risk of ovarian cancer compared to nonaspirin users. The research also found that women who were heavy users of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (Advil) or naproxen (Aleve), over a long period of time had a higher risk of developing ovarian cancer.

The findings were published online today by JAMA Oncology.

Ovarian cancer is the most fatal gynecological cancer, largely due to lack of early detection strategies. It is believed that inflammation that occurs during ovulation plays a role in the development of this cancer. But anti-inflammatory medications, such as aspirin, have been shown to lower the risk of certain types of cancers.

For this study, Shelley Tworoger, Ph.D., associate center director for Population Science at Moffitt, worked with researchers at Huntsman Cancer Institute and the Harvard T.H. Chan School of Public Health to analyze data from more than 200,000 women who took part in the Nurses' Health Studies based at Brigham and Women's Hospital in Boston. Of the participants, 1,054 developed ovarian cancer. Researchers looked at the participants' use of aspirin (325 milligrams), low-dose aspirin (100 milligrams or less), non-aspirin NSAIDs and acetaminophen.

Their analysis found that low-dose aspirin use was associated with a lower risk of ovarian cancer while standard-dose aspirin use was not. Conversely, the data showed that women who took non-aspirin NSAIDs often, defined by at least 10 tablets per week for many years, had an increased risk of developing the disease.

The findings help confirm research published earlier this year by Tworoger in the Journal of the National Cancer Institute. The study, which used data pooled from 13 studies in the Ovarian Cancer Cohort Consortium, included more than 750,000 women, of which 3,500 were diagnosed with ovarian cancer. It found that daily use of aspirin reduced ovarian cancer risk by 10 percent.

"We're not quite at the stage where we could make the recommendation that daily aspirin use lowers ovarian cancer risk. We need to do more research. But it is definitely something women should discuss with their physician," said Tworoger.

###

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,000 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.

Media Contact

Kim Polacek
[email protected]
813-745-7408
@MoffittNews

www.moffitt.org

https://moffitt.org/newsroom/press-release-archive/2018/evidence-mounts-linking-aspirin-to-lower-risk-of-ovarian-cancer/

Related Journal Article

http://dx.doi.org/10.1001/jamaoncol.2018.4149

Share12Tweet8Share2ShareShareShare2

Related Posts

TMolNet: Revolutionizing Molecular Property Prediction

September 21, 2025

NICU Families’ Stories Through Staff Perspectives

September 21, 2025

CT Scans in Kids: Cancer Risk Insights

September 20, 2025

Revealing Tendon Changes from Rotator Cuff Tears

September 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    68 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Key Drivers of Corporate Governance in Burundi’s Cooperatives

Revolutionizing Sustainable Construction: The Role of Cardboard and Earth

TMolNet: Revolutionizing Molecular Property Prediction

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.